Why the study?
Does adjuvant or perioperative immune checkpoint inhibitor therapy improve survival in resectable NSCLC?
Does adjuvant or perioperative immune checkpoint inhibitor therapy improve survival in resectable NSCLC?
Answers are grounded in this paper and cite their sources.
The clinical benefit of the adjuvant phase in perioperative ICI regimens for resectable NSCLC remains uncertain, highlighting the need for phase contribution assessment.
an Oncologic Drugs Advisory Com-Why is it important to mandate phase assessment in NSCLC perioperative regimens?Currently, 5 immune checkpoint inhibitor (ICI)-based regimens have been approved for resectable NSCLC, including 2 adjuvant immunotherapies, 2 perioperative chemoimmunotherapies, and 1 neoadjuvant chemoimmunotherapy.However, the clinical benefit of adjuvant immunotherapy remains uncertain, with IMPower010 and Keynote-091 showing non-significant overall survival [hazard ratio (HR) = 0.97 and 0.87, respectively] [3, 4].Similarly, the BR.31 trial with adjuvant durvalumab did not show an improvement in diseasefree survival [5].
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: